Application of p19/ebi3 complex and its polyclonal antibody in the diagnosis and treatment of systemic lupus erythematosus

A technology for lupus erythematosus and complexes, applied in the direction of antibodies, antibody medical ingredients, medical preparations containing active ingredients, etc., can solve problems such as obvious adverse reactions and poor curative effect of patients

Inactive Publication Date: 2018-04-27
INST OF BASIC MEDICAL SCI ACAD OF MILITARY MEDICAL SCI OF PLA
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The conventional method of treating systemic lupus erythematosus is to use antimalarial drugs, anti-inflammatory drugs and immunosuppressive drugs. When the symptoms are difficult to control, corticosteroids are supplemented to non-steroidal anti-inflammatory agents; although in controlling the disease and preventing the development of the disease It has a significant effect, but most of them have obvious adverse reactions, and the curative effect is not good for some patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of p19/ebi3 complex and its polyclonal antibody in the diagnosis and treatment of systemic lupus erythematosus
  • Application of p19/ebi3 complex and its polyclonal antibody in the diagnosis and treatment of systemic lupus erythematosus
  • Application of p19/ebi3 complex and its polyclonal antibody in the diagnosis and treatment of systemic lupus erythematosus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0071] Example 1 Human IL-12 family cytokine subunits P19 and Ebi3 can form a P19 / Ebi3 complex

[0072] 1. Materials

[0073] Human Ebi3 protein was purchased from Origene (Cat. No. TP723769), human P19 protein was purchased from Origene (Cat. No. TP309680), anti-Ebi3 antibody was purchased from Santa Cruz Biotech (Cat. No. sc-32869), anti-P40 antibody was purchased from Santa Cruz Biotech (Cat. No. sc-7926 ), anti-P19 antibody was purchased from Santa Cruz Biotech (product number sc-50303), anti-c-Jun antibody was purchased from Santa Cruz Biotech company (product number sc-44)

[0074] 2. Method

[0075] 1. Immunoprecipitation

[0076] 1) Agrose-protein A / G cleaning: Take 60 μl Agrose-protein A / G into EP tube (scissor tip), add 500 μl pre-cooled PBS, centrifuge at 4°C, 5000 rpm for 2 min (wash twice).

[0077] 2) Antibody and Agrose-protein A / G pre-incubation: Add 1 μg of anti-Ebi3 antibody, anti-p40 antibody, anti-P19 antibody, and anti-c-Jun antibody to 15 μl of washed ...

Embodiment 2

[0108] Example 2 Mouse IL-12 family cytokine subunits P19 and Ebi3 can form a P19 / Ebi3 complex

[0109] 1. Materials

[0110] Plasmids and Strains:

[0111] P19 / pReceiver-Lv18, Ebi3 / pEZ-LV122X expression plasmid, JM109 strain

[0112] 2. Method

[0113] 1. Primer design

[0114] Amplify the P19ORF primer in the P19 / Ebi3 complex

[0115] Sense strand: 5'-ATGCTGGATTGCAGAGCAGT-3' (SEQ ID NO:5)

[0116] Antisense strand: 5'-GTAAGCTGTTGGCACTAAGG-3'(SEQ ID NO:6)

[0117] Sense strand after adding EcoRI site and protection base:

[0118] 5'-CCGGAATTCATGCTGGATTGCAGAGCAGT-3' (SEQ ID NO: 7)

[0119] Antisense strand after adding XhoI site and protective base:

[0120] 5'-CCGCTCGAGGTAAGCTGTTGGCACTAAGG-3' (SEQ ID NO: 8)

[0121] Primers for amplifying the Ebi3 ORF in the P19 / Ebi3 complex

[0122] Sense strand: 5'-ATGTCCAAGCTGCTCTTCCT-3' (SEQ ID NO:9)

[0123] Antisense strand: 5'-TCAGGGCTTATGGGGTGCAC-3' (SEQ ID NO: 10)

[0124] Sense strand after adding EcoRI site and protecti...

Embodiment 3

[0177] Example 3 Purification and mass spectrometry identification of mouse P19 / Ebi3 complex

[0178] 1. Method

[0179] 1. Co-expression of mouse Ebi3-Flag / P19-His

[0180] Experimental process with reference to embodiment 2.

[0181] 2. Purification of Ebi3-Flag / P19-His

[0182] 1) Nickel column treatment

[0183] Aspirate the 1ml nickel column into the empty chromatographic tube, and add 3ml of equilibration buffer after the liquid in it flows out.

[0184] 2) Add 10ml of the supernatant to the equilibrated nickel column, and repeat the loading of the sample passed through the column 3 times, and take 20 μl of the sample passed through the column for gel running.

[0185] 3. Coomassie brilliant blue staining

[0186] 1) The purified protein was subjected to SDS-PAGE, and the experimental process was as described in Example 1. Soak the gel in fixative for at least 30 min.

[0187] 2) Soak the fixed gel in hot staining solution (dissolve 0.29g Coomassie Brilliant Blue ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a P19 / Ebi3 compound and an application of a polyclonal antibody of the P19 / Ebi3 compound in SLE (systemic lupus erythematosus) diagnosis and treatment. Experiments prove that compared with normal mice, mice with SLE have high-level expression of the P19 / Ebi3 compound, with the application of the polyclonal antibody resistant to P19 / Ebi3 protein, the expression level of antibodies and the number of immune cells in the mice can be reduced, and SLE can be treated through preparation of the antibodies resistant to P19 / Ebi3, so that the P19 / Ebi3 compound and an inhibitor thereof are used for preparing drugs for diagnosing and treating SLE and have excellent development prospects.

Description

technical field [0001] The invention relates to the field of biotechnology, more specifically, the invention relates to the application of P19 / Ebi3 complex and its polyclonal antibody in the diagnosis and treatment of systemic lupus erythematosus. Background technique [0002] Systemic Lupus Erythematosus (SLE) is an autoimmune disease that seriously threatens human health and life, with high mortality and disability rates. Its etiology and pathogenesis are still unclear, but it is generally believed that it is the result of environmental factors acting on the body of a certain genetic background (including different types of expression of histocompatibility, cytokines, cytokine receptors, etc.). Its immunopathological feature is the production of a variety of high and low levels of pathogenic autoantibodies in the body, and lymphocyte apoptosis at the same time. A large number of nuclear contents and ribosomes are released to become self-antigens; antigens and antibodies c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/54C12P21/02C07K16/24G01N33/53A61K39/395A61P37/02
CPCA61K39/39516C07K14/54C07K16/244G01N33/53
Inventor 王仁喜肖鹤韩根成陈国江黎燕沈倍奋侯春梅王小茜魏寅祥刘晓玲张玉
Owner INST OF BASIC MEDICAL SCI ACAD OF MILITARY MEDICAL SCI OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap